Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
pharma · Rheumatoid arthritis · Completely Resected Stage IIB, IIC, and III Melanoma
Celltrion Healthcare Australia
Celltrion Healthcare Australia Pty Ltd
Celltrion Healthcare Australia drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Sydney, AU HQ
9 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, AU
- Employees
- 9
- Programs
- 10
- Drugs
- 44
- Patents
- 0
Celltrion Healthcare Australia pipeline
Portfolio lens on 44 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Celltrion Healthcare Australia drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.
- Mechanism
- Toll-like receptor 7 antagonist
-
ibuprofen
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
metformin hydrochloride
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Mitochondrial complex I (NADH dehydrogenase).
- Target
- Mitochondrial complex I (NADH dehydrogenase)
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
secukinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-17A.
- Target
- Interleukin-17A
- Mechanism
- Interleukin 17A inhibitor
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
Development asset linked to Celltrion Healthcare Australia in public FDA and regional records.
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor